Background: Selection of resistance mutations may play a major role in the development of endocrine resistance. ESR1 mutations are rare in primary breast cancer but have high prevalence in patients treated with aromatase inhibitors (AI) for advanced breast cancer. We investigated the evolution of genetic resistance to the first-line AI therapy using sequential ctDNA sampling in patients with advanced breast cancer.
Introduction
Selection of resistance mutations may play a major role in the development of resistance to therapy. Many examples are described, such as KRAS mutations emerging in colorectal cancer treated with anti-epidermal growth factor receptor (EGFR) therapy [1, 2] and the development of EGFR T790M mutations in patients with non-small-cell lung cancer treated with EGFR inhibitors [3, 4] . In breast cancer, ESR1 mutations are rare in primary disease [5] but have a high prevalence in patients treated with aromatase inhibitor (AI) therapy in the advanced setting. ESR1 mutations mainly occur within the ligand binding domain and result in ligand-independent activation of the estrogen receptor (ER) [6] . They are an acquired mechanism of resistance and mutations in ctDNA predict resistance to AI [7, 8] . In a retrospective study [9] , circulating ESR1 mutations were found in 30.6% of patients at progression on an AI and were detectable in 75% of those patients before progression.
We investigated the development and evolution of genetic resistance to the first-line AI therapy in a prospective study using sequential ctDNA sampling in patients with advanced breast cancer. We find that as well as frequent acquisition of ESR1 mutations, sub-clonal KRAS mutations were found relatively frequently in ctDNA of patients progressing on the first-line AI therapy, suggesting that KRAS mutations could be selected as a potential mechanism of resistance.
Materials and methods

Study design
Eighty-three patients on first-line AI therapy for metastatic breast cancer were enrolled in the prospective plasmaDNA AI study (CCR3297, London-Bromley Research Ethics Committee, REC 10/H0805/50) to collect plasma samples for ctDNA analysis every 3 months on therapy and at disease progression. The objective of the study was to determine the median lead-time between first detection of ESR1 mutation in the plasma and clinical disease progression. All plasma samples were analysed with ESR1 multiplex ddPCR assays. Samples at disease progression were analysed by eTAm-Seq, to investigate the genetics of breast cancer progressing on the first-line AI. Mutations identified by eTAm-Seq were tracked back through samples before disease progression, to study the evolution of mutations on therapy. Written informed consent was obtained from all patients. ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) were assessed in a single laboratory at the Royal Marsden Histopathology department (or reviewed when reported from a referring hospital) using standard criteria.
Plasma collection and processing
In the plasmaDNA AI study, plasma samples were collected every 3 months and at the end of treatment in EDTA Blood Collection Tubes. Samples were processed within 2 h of collection by centrifugation at 1600 g for 20 minutes at room temperature. Plasma was separated from buffy coat and red blood cells, aliquoted and stored at -80 C until DNA extraction.
In the SoFEA trial, baseline blood was collected in EDTA Blood Collection Tubes and processed within 0-9 days of sample collection. Plasma was separated by centrifugation 1600g for 20 minutes. SoFEA samples were analysed previously, demonstrating that archival EDTA plasma samples can be used for ctDNA analysis with ddPCR [8] .
DNA extraction
Following thawing, ctDNA was extracted from 2 or 4 ml of plasma using the MagMax Cell-Free DNA Isolation kit (Thermo A29319) on a Kingfisher Flex Purification System (Thermo) according to manufacturer instructions. The DNA was quantified and stored at -20 C until analysis.
Droplet digital PCR
DNA concentration was estimated in each sample as previously described [7] . For ESR1 mutation analysis, we used two commercially available ddPCR multiplexes from Bio-Rad, multiplex 1 (dHsaMDXE91450042) and multiplex 2 (dHsaMDXE65719815). Multiplex 1 contained FAMlabelled probes for E380Q (c.1138 For KRAS mutation analysis, we used a commercially available ddPCR multiplex from Bio-Rad (Cat Number 1863506). The multiplex assay contains FAM-labelled probes to seven commonly occurring hotspot mutations on codons 12 and 13 of KRAS.
Samples were analyzed using DNA extracted from 1 ml plasma. Reaction volumes were made up to 20 with 10 ll of Bio-Rad ddPCR Supermix for probes, 1 ll of assay and 9 ll nuclease-free water, then partitioned to a mean of 15 000 droplets using a ddPCR Auto Droplet Generator (Bio-Rad). For ESR1 mutation analysis, the following conditions were used: 95 C for 10 minutes followed by 40 cycles of 95 C for 15 seconds, 52
C for 60 seconds, ramp rate 2.5 C/second and final incubation 98 C for 10 minutes. For KRAS mutation analysis, the following conditions were used: 95 C for 10 minutes followed by 40 cycles of 94 C for 30 seconds, 55 C for 60 seconds, ramp rate 2.5 C/second and final incubation 98 C for 10 minutes. Subsequent analysis was done on a BioRad QX200 droplet reader and analysed using QuantaSoft software v1.7.4.0917 (Bio-Rad). A multiplex assay was called mutation positive if there were at least two FAM-positive droplets. Samples were called negative if there were at least 300 wild-type alleles detected and <2 FAMpositive droplets. If this criterion was not met, it was repeated or failed if there was insufficient material to repeat.
InVision
TM /eTAm-seq analysis
The InVision liquid biopsy platform combines efficient next-generation sequencing (NGS) library preparation and statistical algorithms to identify and quantify low frequency tumour-derived single nucleotide variants (SNVs), insertion/deletions (Indels) and copy number variations in cell-free DNA, based on methods described previously [3, 10] . NGS libraries were prepared using a two-step amplification process, with primers targeting 36 cancer-related genes designed to hotspot and entire coding regions of interest (supplementary Figure S1 , available at Annals of Oncology online). The panels (v1.4/v1.5) are optimised for amplification of highly fragmented DNA with amplicon sizes ranging 72-154 bp. Pooled libraries were quantified using Kapa Library Quantification Kit, and 1.8pM libraries analysed on an Illumina NextSeq 500 (300 cycle PE). Sequencing files were analysed using the Inivata Somatic Mutation Analysis (ISoMA) analytical pipeline (V1.15-1.17), and sequencing reads were clipped, merged and aligned. Coding and splice-site mutations in SNVs and Indels were annotated using Variant Effect Predictor (VEP) using the canonical transcript for each gene. Sub-clonal mutations were defined as mutations with an aggregate allele frequency (AF) <0.25 of driver mutation AF identified in the analyzed samples.
Orthogonal validation of detected mutations by eTAm-Seq was performed using ddPCR as described above. KRAS, PIK3CA and TP53 mutations were validated using either commercially available assays or inhouse designed assays as described previously [11] .
Statistical analysis
For each of the markers tested, the proportion of patients with the mutation were reported with 95% confidence interval (CI). The study was powered assuming a 15% incidence of activating mutation of ESR1, with a minimum of 50 patients to calculate the actual proportion that were ESR1 mutation positive with 95% CI of 69.9%. Validation of mutations found in the plasmaDNA AI prospective study, if recurrent mutations were identified at sufficiently high prevalence, was planned in the SoFEA phase III trial that has been described previously [12] . Briefly, the SoFEA study was a multicentre, randomized phase III trial in postmenopausal women with advanced, hormone receptor positive breast cancer who had progressed on a non-steroidal AI. All patients had demonstrated prior sensitivity to AIs, and were randomized to fulvestrant plus anastrozole, fulvestrant plus placebo, or exemestane.
The SoFEA validation analysis would provide a level of precision for mutation incidence around a 95% CI of 65.5%, based on a proportion of 10%, or 67.5% based on a proportion of 20% (n ¼ 117 patients baseline plasma with sufficient quantity to analyse). Progression-free survival (PFS) and overall survival (OS) were defined in the main SoFEA trial [12] . To determine whether KRAS mutations were prognostic for PFS and OS, Cox proportional hazards models were used. The proportional hazards assumption made by using the Cox model was tested using Schoenfeld's residuals and was found to hold. Kaplan-Meier curves were plotted (mutant versus wild-type), median PFS time and unadjusted HR with 95% CI reported and groups compared using the log-rank test. All statistical analyses were performed with GraphPad Prism (version 6.0), Stata (version 13.1) or R. Lead-time was calculated using the Turnbull estimator.
Results
ESR1 mutations are frequently subclonal and polyclonal at progression on AI
Eighty-three patients with ER-positive metastatic breast cancer on first-line AI therapy were enrolled into a prospective study to collect plasma samples for ctDNA analysis every 3 months and at disease progression ( Figure 1A) . The clinical and pathological characteristics of the study cohort are described in Figure 1B . We initially studied the evolution of ESR1 mutations on AI therapy, using ultra-high sensitivity multiplex ddPCR assays for seven commonly occurring ESR1 mutations to track these mutations in plasma until clinical progression. Of the 39 patients who progressed on the first-line AI, 56.4% (22/39, 95% CI, 39.6% to 72.2%) had ESR1 mutations detectable at progression. In patients with ESR1 mutations detected, the mutations were polyclonal in 40.9% (9/22, 95% CI, 20.7% to 63.7%) of patients ( Figure 2) . In serial tracking before progression, ESR1 mutations were detectable in plasma before progression in 86.4% (19/22, 95% CI, 65.1% to 97.1%) patients, with ESR1 mutations detectable a median of 6.7 months (95% CI 3.7-NA) before clinical progression (Figure 4) . In patients who progressed on AI, all patients who had ESR1 mutations detected before progression also had ESR1 mutations detected at progression, suggesting early detection of ESR1 mutations robustly predicted the presence of the mutation at progression. ESR1 mutations were detectable in 15.2% (5/33) patients who had not yet clinically progressed ( Figure 1B ).
AI resistant breast cancers are genomically diverse
We investigated the genetics of breast cancers progressing on first-line AI, with eTAm-Seq deep sequencing of ctDNA from progression plasma samples (Figure 3) . Consistent with other studies [5, 13, 14] )] mutations were the most frequent mutations detected. ESR1 mutations were identified in more samples by ddPCR than by eTAm-Seq. Of the 10 discordant cases, one ESR1 mutation detected by eTAm-Seq but not ddPCR occurred at an AF of 0.002, whereas nine ESR1 mutations detected only by ddPCR occurred at AF's ranging from 0.0004 to 0.032. For one case, there was weak evidence of an ESR1 mutation but this was below the eTAm-Seq calling threshold. These cases had lower mutant copies per ml in ddPCR compared with concordant cases (median 14.3 versus 51.5, respectively, P ¼ 0.048 Mann-Whitney U test), suggesting that ddPCR was detecting low levels of ESR1 mutation in ctDNA. In patients with additional driver mutations detected in ctDNA, ESR1 mutations were sub-clonal in 72.2% (13/18, 95% CI, 46.5% to 90.3%) of patients, found at aggregate relative AF <0.25, with ESR1 mutation diversity increasingly detectable at the point of progression Error corrected ctDNA sequencing of plasma samples taken after progression on the first-line aromatase inhibitor (AI). Mutations identified in plasma DNA by eTAm-Seq error corrected sequencing, with ESR1 mutation analysis by ddPCR. Discordant cases for ESR1 between ddPCR and ctDNA sequencing had lower mutant copies per ml in ddPCR compared with concordant cases (median 14.3 versus 51.5, respectively, P ¼ 0.048 Mann-Whitney U test) and likely represent very low levels of mutant copies and random sampling. 8037 also had FGFR1 and ERBB2 amplification identified. Of 36 progression plasma samples sequenced, 25 with mutations are displayed, 11 plasma samples with no mutations detected are not displayed. Numbers in boxes represent allele fraction for indicated gene. Where there are multiple mutations detected in the same gene, indicating polyclonality (P), aggregate allele fractions are given.
compared with samples taken before progression (Figure 2 ). In patients with polyclonal mutations, individual mutations were observed to be on different DNA strands in eTAm-Seq, further supporting the sub-clonality of the observed ESR1 mutations. Deep ctDNA sequencing of progression samples identified previously unrecognized genetic diversity. Polyclonal KRAS mutations were identified in two patients, 8005 (p.G12V, p.G12S) and 8023 (p.G12V, p.G12C, p.G12R), a monoclonal HRAS mutation (p.G12V) in one patient and a monoclonal NRAS mutation (p.G12D) in another one. An activating p.R248C FGFR3 mutation was identified in a further patient ctDNA sample. Sequencing or ddPCR of ctDNA obtained from plasma identified RAS mutations in 15.4% (6/39, 95% CI, 5.9% to 30.5%) of patients [four KRAS (two of which were polyclonal], one monoclonal HRAS and one monoclonal NRAS) ( Figure 5) . In patients where an additional driver mutation was detected in ctDNA, all identified RAS mutations were sub-clonal. In two patients with KRAS mutations detected at progression, primary tumour was available, with the KRAS mutation being undetectable in both patients.
Clonal Haematopoesis of Indeterminate Potential (CHIP) is an age-related clonal expansion that is detectable in a high proportion of ageing people [15, 16] . Mutations arising from CHIP may be detected in ctDNA analysis and present a potential confounder to discovery of resistance mutations in ctDNA. Although KRAS mutations are not a classic CHIP mutation, they are reported at low level. To ascertain whether detected KRAS mutations were arising from ctDNA or CHIP, we tracked KRAS mutations back through serial samples before progression ( Figure 5 ). KRAS mutations arose in line with driver and ESR1 mutations at disease progression, demonstrating that the KRAS mutations were detected in ctDNA. In contrast, a TP53 mutation detectable at progression was shown to arise from CHIP with high-likelihood, as the AF of the mutation stayed constant through serial tracking, whilst mutations arising from ctDNA rose to the point of progression (Figure 2 ).
Identified RAS mutations are selected on AI therapy
To validate our novel discovery of KRAS mutations in AI resistant cancer, and to assess clinical significance of KRAS mutations in patients who progressed on endocrine therapy, we analysed baseline plasma samples from the phase III SoFEA study by ddPCR. We retrospectively analysed KRAS mutational status on 117 available baseline plasma samples of the 723 patients enrolled on the study. We investigated the association of KRAS mutations detected in ctDNA and clinical outcome. These samples had previously been analysed for ESR1 mutation status [8] . KRAS mutational status was successfully interrogated in 96.6% (113/ 117) of available plasma samples, with KRAS mutations detected in 21.2% (24/113, 95% CI, 14.1% to 29.9%) of patients, with no KRAS mutations detected in controls (supplementary Table S2 , available at Annals of Oncology online). 19.0% (8/42, 95% CI, 8.6% to 34.1%) of ESR1 mutant cancers also had KRAS mutations. KRAS mutations were detected at low levels in the majority of patients. There were no significant differences in baseline characteristics between patients with and without KRAS mutations (supplementary Table S3 , available at Annals of Oncology online).
There was no evidence that KRAS mutation status was prognostic for PFS or OS in patients who had progressed on an AI. Median PFS was 3.7 months (95% CI, 2.7-11.5) for patients with KRAS mutations and 4.6 months (95% CI, 3.0-6.5) for patients with wild-type KRAS (unadjusted hazard ratio ¼ 1.04, 95% CI, 0.65-1.67; P ¼ 0.86). Median OS was 22.5 months (95% CI, 12.2-32.4) for patients with KRAS mutations and 21.2 months (95% CI, 17.6-26.1) for patients with wild-type KRAS (unadjusted hazard ratio ¼ 1.16, 95% CI, 0.66-2.03; P ¼ 0.61) ( Figure 6 ).
Discussion
In the prospective plasmaDNA AI study, we demonstrate that ER-positive advanced breast cancer progressing on AI shows substantial genetic diversity, with a high rate of ESR1 mutations and a previously un-described high rate of mutations in KRAS and a classical activating mutation in FGFR3. Many selected mutations are demonstrated to be sub-clonal, although our findings identify a potential major role for selected KRAS mutations in resistance to AI therapy in the treatment of advanced breast cancer.
In this cohort of patients progressing on first line AI, ESR1 mutations are found at high prevalence in plasma, detectable in over half of patients. Resistance to therapy can be anticipated with a long lead-time over clinical progression, with ESR1 mutations detectable before progression in 86.4% of patients. These results are consistent with a prior retrospective study that reported ESR1 mutations were detectable in 75% of patients before progression [9] . This prior study reported a lower frequency of ESR1 mutations at progression on an AI but only four ESR1 mutations were analysed using 4 ng preamplified DNA which likely explains the higher frequency reported here. The incidence of ESR1 mutations we report is in line with the rate we previously reported in the SoFEA study, with ESR1 mutations detected in 39.1% of baseline samples [8] .
We show that many ESR1 mutations detected in plasma are likely sub-clonal in the cancer, with the aggregate allele fraction of ESR1 mutations frequently substantially lower than that of other identified driver mutations. This suggests that in an individual patient, ESR1 mutations may not be the sole driver of resistance in the cancer. Multiple drugs that degrade the mutant ER are in early clinical, and pre-clinical development, and this finding emphasises the importance of assessing clonal dominance of ESR1 mutations in clinical development. Also, due to the subclonal nature of these mutations, the amount of plasma DNA analysed may have a major impact on frequencies of ESR1 mutations identified.
KRAS mutations are identified frequently in colorectal cancers with resistance to EGFR directed therapy [1, 2] , but previously have not been identified as a major mechanism of resistance in ER positive breast cancer. We show that selection of KRAS activating mutations is a potential novel mechanism of resistance to AI, with a substantial prevalence of 21.2% (24/113) in the SoFEA validation series. KRAS mutations are identified in approximately 2% of primary ER-positive breast cancer [5, 13] , and KRAS mutations are undetectable in the primary of two patients with selected In two patients with KRAS mutations detected at progression primary tumour was available, with the KRAS mutation being undetectable in both patients.
KRAS mutations, suggesting selection by therapy. The KRAS mutations identified are frequently sub-clonal, possibly due to geographic development of KRAS mutations in individual metastases. Multiple prior studies have linked activation of MAP kinase pathway signaling to resistance to endocrine therapy [17, 18] , suggesting the KRAS mutations may drive resistance to endocrine therapy in individual sub-clones. In SoFEA the presence of a KRAS mutation detected in ctDNA had no impact on PFS or OS, although this analysis used a relatively small number of samples and would need confirmation in a larger set. This finding suggests the importance of determining whether sub-clonal KRAS mutations continue to expand through subsequent therapy, or whether the mutations become undetectable once endocrine therapy is ceased, which will be an important area of future research. This study has limitations. Some patients joined the study mid-AI therapy and had ESR1 mutations detected at the first sample. Although this was taken into account when calculating lead-time to progression, this adds imprecision to the median estimate of lead-time. There were a relatively small number of progression samples in the plasma AI study and it was not possible to perform sequencing on all progression samples due to amounts of DNA available. Although the ctDNA sequencing strategy we employ substantially expanded our ability to investigate the genetics of AI resistant cancer, leading to the discovery of KRAS mutations, the panel covered a limited number of genes. There may be other relevant selected mutations present at progression on AI that were not detected in this panel. Most of the KRAS mutations detected were present at low levels, and although some mutations were present at relatively high level it was not possible due to limited number of high level mutations to assess whether there is a different impact on outcome for those with high levels of KRAS mutation. Our study demonstrates the potential of ctDNA analysis in describing the genetics of drug resistant disease, and the power of combining prospectively collected sample sets with high depth discovery ctDNA sequencing. Selected genetic mechanisms of resistance are frequent in resistance to first line AI therapy; ESR1 mutations are found at high prevalence in this setting, along with high frequency sub-clonal KRAS mutations. AI resistant cancers are genetically heterogeneous and may consist of several clones that may limit the effectiveness of subsequent targeted therapies that target only one of the clones.
